Abstract: An icon display module includes a light blocking structure, a first light-emitting element, a second light-emitting element, a first light-guiding pattern structure and a second light-guiding pattern structure. The light blocking structure includes an accommodation space and a first light-blocking part. The accommodation space is divided into a first region and a second region by the first light-blocking part. When the first light-emitting element emits a first light beam, the first light beam is guided by the first light-guiding pattern structure and the second light-guiding pattern structure and projected on the target. Consequently, a first icon and a second icon are shown on the target. When the second light-emitting element emits a second light beam, the second light beam is guided by the first light-guiding pattern structure and projected to the target. Consequently, the first icon is shown on the target.

Abstract: An icon display module includes a light blocking structure, a first light-emitting element, a second light-emitting element, a first light-guiding pattern structure and a second light-guiding pattern structure. The light blocking structure includes an accommodation space and a first light-blocking part. The accommodation space is divided into a first region and a second region by the first light-blocking part. When the first light-emitting element emits a first light beam, the first light beam is guided by the first light-guiding pattern structure and the second light-guiding pattern structure and projected on the target. Consequently, a first icon and a second icon are shown on the target. When the second light-emitting element emits a second light beam, the second light beam is guided by the first light-guiding pattern structure and projected to the target. Consequently, the first icon is shown on the target.

Abstract: A lactic acid bacterial composition for modulating immune cell differentiation and/or reducing pro-inflammatory cytokine secretion includes: (a) a Limosilactobacillus reuteri GL-104 strain; and (b) a Lacticaseibacillus rhamnosus F-1 strain; wherein the GL-104 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M209138, and the F-1 strain is deposited at the China Center for Type Culture Collection with a deposition number CCTCC M2011124. Additionally, a method for treating or preventing allergic rhinitis by administering the foregoing composition to a subject in need thereof is also provided.

Abstract: The present invention provides a topical composition having a fermented product of lactic acid bacteria synbiotics as an active ingredient. The fermented product of lactic acid bacteria synbiotics is obtained by performing a fermenting step with lactic acid bacteria and a deactivating step on a fermenting substrate. The lactic acid bacteria are consisting of Lactobacillus salivarius subsp. salicinius AP-32, Bifidobacterium animalis subsp. lactis CP-9 and Lactobacillus acidophilus TYCA06. The fermenting substrate includes animal protein, plant protein and/or plant extracts. The aforementioned fermented product of lactic acid bacteria synbiotics can effectively inhibit the growth of Staphylococcus aureus and/or Propionibacterium acnes, and can be used in the topical composition.

Abstract: A luminous touch pad includes a covering plate, a circuit board, a light guide structure and a first light-shading adhesive. The covering plate includes a first surface and a second surface. The circuit board is located under the covering plate. The circuit board includes a third surface and a fourth surface. The light guide structure is arranged between the covering plate and the circuit board. The light guide structure includes a lateral surrounding surface. An adhesive receiving space is defined by the lateral surrounding surface, a portion of the second surface and a portion of the third surface collaboratively. The first light-shading adhesive is disposed within the adhesive receiving space and arranged around the light guide structure. The first light-shading adhesive is contacted with the portion of the second surface, the portion of the third surface and the lateral surrounding surface.

Abstract: A probiotic culture is prepared by cultivating a probiotic mixture in a collagen solution. The probiotic mixture includes Lactobacillus acidophilus TYCA06 deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 15210, Lactobacillus salivarius subsp. salicinius AP-32 deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium animalis subsp. lactis CP-9 deposited at the CCTCC under an accession number CCTCC M 2014588, in a ratio of colony forming units which ranges from 1:0.125:0.125 to 1:8:8. Use of the probiotic culture for improving skin condition and for inhibiting pathogenic infection is also provided.

Abstract: The present invention discloses a method for maintaining or improving gastrointestinal condition, which includes: administering a lactic acid bacterial composition to a subject in need thereof, wherein the lactic acid bacterial composition comprises: a Lactobacillus paracasei ET-66 strain with a deposition number CGMCC 13514. The present invention also discloses a method for maintaining or improving gastrointestinal condition, which includes: administering a lactic acid bacterial fermentation composition to a subject in need thereof, wherein the lactic acid bacterial fermentation composition comprises: a fermentation product of a Lactobacillus paracasei ET-66 strain.

Abstract: The present invention discloses an anti-aging composition, which includes: (a) isolated lactic acid bacterial strains or a fermented product thereof; and (b) an excipient, a diluent, or a carrier; wherein the isolated lactic acid bacterial strains include: Bifidobacterium bifidum VDD088 strains, Bifidobacterium breve Bv-889 strains, and Bifidobacterium longum BLI-02 strains. The present invention further provides a method for preventing aging by administering the foregoing anti-aging composition to a subject in need thereof.

Abstract: Disclosed herein is a probiotic composition that includes Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9, which are deposited at the China Center for Type Culture Collection (CCTCC) respectively under accession numbers CCTCC M 2011127, CCTCC M 2011128, and CCTCC M 2014588. A number ratio of Lactobacillus salivarius subsp. salicinius AP-32, Lactobacillus johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 ranges from 1:0.1:0.1 to 1:1:8. Also disclosed herein is use of the probiotic composition for alleviating type 1 diabetes mellitus (T1DM).

Abstract: A light guide module includes a light guide plate, a light-emitting element and a covering layer. The light guide plate includes plural first light-guiding dots and plural second light-guiding dots. The light-emitting element is installed on a lateral edge part of the light guide plate. The covering layer includes a non-shading region, a separation region and a shading region. The plural first light-guiding dots of the light guide plate are aligned with the non-shading region of the covering layer. The plural second light-guiding dots of the light guide plate are aligned with the shading region of the covering layer. The plural second light-guiding dots are covered by the shading region of the covering layer.

Abstract: Disclosed herein is a method for alleviating atopic dermatitis using a composition containing at least one lactic acid bacterial strain. The at least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus salivarius subsp. salicinius AP-32 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium animalis subsp. lactis CP-9 which is deposited at the CCTCC under an accession number CCTCC M 2014588.

Abstract: The present invention provides a lactic acid bacteria composition, which comprises: a Lactobacillus plantarum PL-02 strain, a Lactobacillus acidophilusTYCA06 strain, a Lactobacillus casei CS-773 strain, and a physiologically acceptable excipient, diluent, or carrier. All of the strains are deposited at the China General Microbiological Culture Collection Center.

Abstract: The present invention discloses a method for maintaining or improving gastrointestinal condition, which includes: administering a lactic acid bacterial composition to a subject in need thereof, wherein the lactic acid bacterial composition comprises: a Lactobacillus paracasei ET-66 strain with a deposition number CGMCC 13514. The present invention also discloses a method for maintaining or improving gastrointestinal condition, which includes: administering a lactic acid bacterial fermentation composition to a subject in need thereof, wherein the lactic acid bacterial fermentation composition comprises: a fermentation product of a Lactobacillus paracasei ET-66 strain.

Abstract: The invention provides a method of increasing an amount of oral immunoglobulin A (IgA) and/or inhibiting oral pathogens in a subject in need thereof, which utilizes a composition including a therapeutically effective amount of probiotics as an effective ingredient. The probiotics include Lactobacillus plantarum LPL28, which can efficiently increase the amount of oral IgA and/or inhibit the oral pathogens, and thus have a potential to prevent teeth cavities and/or periodontal diseases.

Abstract: The present invention provides a lactic acid bacterial composition for inhibiting the activity of Escherichia coli and/or treating or preventing jaundice, the composition including: a Bifidobacterium animalis subsp. lactis CP-9 strain and a Lactobacillus salivarius subsp. salicinius AP-32 strain. The present invention further provides a method for inhibiting growth of Escherichia coli, the method including the step(s) of: administering the foregoing lactic acid bacterial composition to a subject in need thereof. The present invention additionally provides a method for treating or preventing jaundice, the method including the step(s) of: administering the foregoing lactic acid bacterial composition to a subject in need thereof.

Abstract: Disclosed herein is a method for alleviating atopic dermatitis using a composition containing at least one lactic acid bacterial strain. The at least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus salivarius subsp. salicinius AP-32 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium animalis subsp. lactis CP-9 which is deposited at the CCTCC under an accession number CCTCC M 2014588.

Abstract: The present invention discloses an anti-aging composition, which includes: (a) isolated lactic acid bacterial strains or a fermented product thereof; and (b) an excipient, a diluent, or a carrier; wherein the isolated lactic acid bacterial strains include: Bifidobacterium bifidum VDD088 strains, Bifidobacterium breve Bv-889 strains, and Bifidobacterium longum BLI-02 strains. The present invention further provides a method for preventing aging by administering the foregoing anti-aging composition to a subject in need thereof.

Abstract: The present invention provides a lactic acid bacterial composition for inhibiting the activity of Escherichia coli and/or treating or preventing jaundice, the composition including: a Bifidobacterium animalis subsp. lactis CP-9 strain or a Lactobacillus salivarius subsp. salicinius AP-32 strain. The present invention further provides a method for inhibiting growth of Escherichia coli, the method including the step(s) of: administering the foregoing lactic acid bacterial composition to a subject in need thereof. The present invention additionally provides a method for treating or preventing jaundice, the method including the step(s) of: administering the foregoing lactic acid bacterial composition to a subject in need thereof.

Abstract: Disclosed herein is a probiotic culture prepared by cultivating a probiotic mixture in a collagen solution. The probiotic mixture includes, in a number ratio of, Lactobacillus acidophilus TYCA06 deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 15210, to Lactobacillus salivarius subsp. salicinius AP-32 deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and to Bifidobacterium animalis subsp. lactis CP-9 deposited at the CCTCC under an accession number CCTCC M 2014588, which ranges from 1:0.125:0.125 to 1:8:8. Also disclosed herein is use of the probiotic culture for improving skin condition and for inhibiting pathogenic infection.

Abstract: A composition, which comprises at least one of an AP-32 strain of Lactobacillus salivarius subsp. salicinius, a BLI-02 strain of Bifidobacterium longum subsp. infantis and fermentation metabolites thereof, has a physiological activity of elevating ability of brain tissue. The present invention may be used in form of a food composition or a pharmaceutical composition to elevate the ability of brain tissue.